From Wikipedia, the free encyclopedia
Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract. As of September 2009 , the drug is undergoing Phase II/III clinical trials.
- ^ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666.
- ^ ClinicalTrials.gov